Treatment outcomes of nontuberculous mycobacterial pulmonary disease in lung transplant recipients.
Transpl Infect Dis
; 23(4): e13679, 2021 Aug.
Article
en En
| MEDLINE
| ID: mdl-34184393
ABSTRACT
BACKGROUND:
Lung transplant (LTX) recipients are at risk miscellaneous infections, among whom the clinical significance of nontuberculous mycobacteria (NTM) is increasingly recognized. Despite anti-mycobacterial therapy becoming standardized worldwide, there is a lack of data on treatment outcomes in LTX recipients who develop NTM-pulmonary disease (PD). We aimed to review the treatment outcomes of NTM-PD among LTX recipients in our center.METHODS:
Patients who underwent LTX from January 2013 to December 2014 were consecutively enrolled in the retrospective cohort, with follow-up of data retrieved to December 2017. Clinical and radiological improvement and culture conversion after anti-mycobacterial therapy were reviewed in those who developed post-transplant NTM-PD.RESULTS:
Sixteen of 230 LTX recipients developed post-transplant NTM-PD. Ten of 16 patients with post-transplant NTM-PD were treated with macrolide-containing anti-mycobacterial therapy, leading to clinical improvement in 5/10 (50%), radiological improvement in 5/10 (50%) and culture conversion in 6/10 (60%) patients.CONCLUSION:
Anti-mycobacterial therapy may relieve pulmonary symptoms and reduce microbial load among individuals with post-transplant NTM-PD.Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Enfermedades Pulmonares
/
Infecciones por Mycobacterium no Tuberculosas
Tipo de estudio:
Observational_studies
Límite:
Humans
Idioma:
En
Año:
2021
Tipo del documento:
Article